Please find the attached Intimation for Closure of Trading Window
Awaiting price reaction for this filing.
Cresanto Global Ltd (formerly Raymed Labs Limited) has informed BSE that the trading window for its securities will be closed from 1st January 2026 until 48 hours after the declaration of unaudited financial results for the quarter ending 31st December 2025. The restriction applies to all Directors, Officers, Designated Employees, and their immediate relatives, who are barred from buying, selling, or pledging company shares during this period. This is a routine compliance filing under SEBI's Prohibition of Insider Trading Regulations, 2015, made ahead of the upcoming Q3 FY26 results. The date of the board meeting to approve the Q3 results will be communicated separately. The intimation was signed by Managing Director Prashant Nathmal Bajaj on 27th December 2025.
This is a routine regulatory disclosure with no direct impact on shareholders. It signals that Q3 FY26 results are expected soon, and insiders are barred from trading until results are publicly announced — a standard measure to prevent insider trading.